Navigation Links
Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
Date:8/28/2013

SAN DIEGO, Aug. 28, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which is focused on the commercialization of drug formulations through a growing proprietary network of compounding pharmacy relationships and by utilizing the FDA 505(b)(2) development pathway, has announced it has acquired intellectual property, including a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents. Imprimis believes this formulation has the potential to significantly impact the fast-growing $5 billion global cataract surgery drug market. The acquisition allows Imprimis to pursue the commercial development of certain proprietary innovations and also provides Imprimis with a preemptive right on additional Novel Drug Solutions and Eye Care Northwest intellectual property and drug development opportunities. 

Imprimis CEO, Mark L. Baum, said, "This is an important acquisition of a novel drug formulation with an important clinical track record. It is gratifying to see our Asset Review Methodology (ARM™) at work. We believe that going forward our growing group of drug discovery and development relationships will bring additional clinically relevant formulations to our company, and these assets will drive additional value for our shareholders. We are in the process of conducting a feasibility assessment related to the development of this asset, together with a team which consists of leaders from the ophthalmic development and regulatory community. Imprimis will continue to develop partnerships with inventors and secure assets which will support our strategic objectives."

The target compound, referred to as IPI-140, is based on a novel combination of moxifloxacin and triamcinolone.  IPI-140 was co-invented b
'/>"/>

SOURCE Imprimis Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
2. Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013
3. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
4. Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
5. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
6. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
7. Imprimis Announces Key Leadership Appointments
8. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
9. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
10. Imprimis to Begin New Study of Its Topical Analgesic Drug
11. Imprimis Names Two Experts To Its Science And Regulatory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... (NYSE: DHR ) announced today that Henk ... and Amir Aghdaei and Henrik Roos have each been ... In his new role, Henk van Duijnhoven will ... Group and Sybron Dental Specialties.  Danaher,s Dental segment generated ...
... ALISO VIEJO, Calif., April 5, 2011 Avanir Pharmaceuticals, Inc. ... will present an overview of the company at the Future Leaders ... Location: Millennium Broadway Hotel & Conference Center, New York, ... Presentation time: 2:00pm ET A live ...
Cached Medicine Technology:Danaher Announces Executive Appointments 2
(Date:4/22/2014)... in massive health care spending, a new RAND study ... to incentivize pharmaceutical companies and device makers to develop ... existing medical technologies and their use, a new study ... and medical devices get created in the first place. ... with as little loss of health as possible and ...
(Date:4/22/2014)... Mich. Nearly 7 in 10 Americans support ... new national survey by researchers at the University of ... children under the age of 18 at home, and ... likely than other adults to support universal coverage of ... in the Journal of the American Medical Association ...
(Date:4/22/2014)... This news release is available in German . ... F. Perutz Laboratories of the University of Vienna and the ... Zurich, have now shown how double stranded RNA, such as ... a cell. During the immune response against viral infection, the ... cytoplasm. There it modifies viral RNA to inhibit reproduction of ...
(Date:4/22/2014)... When mothers are exposed to trauma, illness, alcohol or ... molecular trigger in brain cells that can go awry ... and some forms of autism. , Until now, it ... the cells of a developing brain. Past studies have ... alcohol or drug abuse or she experiences some trauma ...
(Date:4/22/2014)... chronic inflammatory disorders of the intestine that result in ... in the U.S., and while there are treatments to ... , Now, Cincinnati Cancer Center and University of Cincinnati ... in her lab have done what is believed to ... important function for the Ron receptor, a cell surface ...
Breaking Medicine News(10 mins):Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3Health News:Life stressors trigger neurological disorders, researchers find 2Health News:Two genes linked to inflammatory bowel disease 2
... the only over the counter treatment for chronic and acute wounds. ... contamination of wounds and speeds up the healing process. ... ... development of Wound-Be-Gone, all skin injuries, especially large, chronic wounds, can ...
... WASHINGTON, Nov. 18 Over 2 million low-income Medicare,beneficiaries ... in,January. Changes to the 2009 Medicare Part D plans ... premiums they cannot afford or limit,access to their prescriptions, ... Law Center (NSCLC). Part D open enrollment runs from ...
... But research is preliminary, scientists stress , , TUESDAY, Nov. ... a genetic trait that could provide an early indication ... The research, reported Tuesday at the American Association for ... the preliminary stages. , Still, "the benefit would hopefully ...
... A study appearing in Journal of the American ... their healthcare benefits may affect their ability to access ... delay or avoid seeking care. , In the ... across the United States were surveyed. About one-third of ...
... Resource So Families of ,Bad, Children Can Survive - and ... BEACH, Fla., Nov. 18 The holidays should bring peace, ... the season can foster difficult, even disorderly conduct among troubled ... a family gathering and leave parents asking, "What did I ...
... SEATTLE, Nov. 18 Seattle University ... million Opus Prize to Marguerite "Maggy",Barankitse for her ... of,ethnic strife in Burundi, Africa. Two $100,000 winners ... Community and Center for the,Development of Central America, ...
Cached Medicine News:Health News:A Revolution in Wound Healing, Wound-Be-Gone Now the Only Over the Counter Treatment for Chronic and Acute Wounds 2Health News:A Revolution in Wound Healing, Wound-Be-Gone Now the Only Over the Counter Treatment for Chronic and Acute Wounds 3Health News:2009 Medicare Part D Premiums to Rise Dramatically: Over 2 Million Low Income Beneficiaries At Risk 2Health News:Genetic Trait Could Predict Lung Cancer 2Health News:New Site DrNorm.com Offers Hope and Healing to Parents of 'Difficult' Children During Holiday Season & Beyond 2Health News:New Site DrNorm.com Offers Hope and Healing to Parents of 'Difficult' Children During Holiday Season & Beyond 3Health News:Seattle University in Partnership With the Opus Prize Foundation Award $1 Million Opus Prize 2
Complete Cataract Competence , OPMI VISU 140 is compact, good and economical. It's everything a cataract specialist needs today....
BD Vacutainer® Specialty Tubes - Acid Citrate Dextrose (ACD)...
... BD Vacutainer® SST™ Tubes ... a polymer gel for ... used for serum determinations ... provide an efficient means ...
MONOJECT Red/Yellow Mottled Stopper...
Medicine Products: